SF3B1 and myelodysplastic syndrome: The International Working Group for the Prognosis of MDS assessed the impact of SF3B1 mutations in 3749 MDS patients (795 SF3B1-mutated) and concluded that SF3B1-mutated MDS represented a unique MDS subtype with favorable outcomes regardless of the presence of ring sideroblasts [138].